+ Watch PLX
on My Watchlist
A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.
PLX has a too high valuation compared to its sales potential. Its current sales are nil, and so is one of the most loss making companies.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions